Approach

We aim to disable immunosuppressive signals within the tumor microenvironment while avoiding on-target, off-tumor activity.

Lack of selectivity has posed a significant challenge to expanding the range of immunotherapy options for patients. Checkpoints and other immunosuppressive signals are promising therapeutic targets, but widespread expression on tissues beyond the tumor microenvironment often leads to poor drug-like properties and narrow therapeutic windows that diminish efficacy and pose safety risks.

TMAb™ Platform

The TMAb Platform is designed to overcome this selectivity challenge by creating conditionally active antibodies that are intended to selectively activate within the low-pH tumor microenvironment.

HQ: 1405 Research Blvd, Suite 125,
Rockville, MD 20850

MA: 22 Boston Wharf Rd, 7th Floor,
Boston, MA 02210